VANCOUVER, BC / ACCESSWIRE / February 6, 2017 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) has retained the services of DuVal & Associates, P.A., a Minneapolis-based, regulatory law firm focused on counsel within the medical device and pharmaceutical industries. In addition to its strategic advisory role, DuVal & Associates will represent CVR throughout the process of FDA approvals and clearances for its “Carotid Stenotic Scan (CSS)” device.
With over thirteen years of experience working on behalf of clients seeking FDA clearances and approvals, DuVal & Associates has established a worldwide reputation for streamlining regulatory procedures and right-sizing FDA’s demand for data. Their expertise in managing submissions, including formal filings, quantitative and qualitative trial data analysis, and in-person negotiations between the FDA and client will guide CVR with best practices for preparation and efficiency. CVR Medical Chief Operating Officer Tony Robinson expresses confidence in the results the partnership will help achieve, stating, “As we approach the point of FDA submissions for the CSS, we feel our position could not be stronger with regard to our legal regulatory support. Mark DuVal and his staff have an incredible track record of success, and we look forward to having their familiarity with and insight into this process.”
Mark DuVal, President and founder of DuVal & Associates, states, “We are truly excited to be working with CVR. We always embrace the challenge of helping companies meet FDA requirements at the lowest cost and fastest times possible. As an organization, we are meeting face to face with representatives from the FDA more often than any other group in the country, and we do it to ensure great products like [the CSS] become available to patients and their physicians as soon possible.”
For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
About DuVal & Associates, P.A.
DuVal & Associates is a boutique law firm located in Minneapolis, Minnesota that specializes in FDA regulations for products at all stages of the product life cycle. DuVal’s clientele includes companies that market and manufacture pharmaceuticals, medical devices, biologics, nutritional supplements and foods. These clients range in size from global Fortune 500 companies to small start-ups. For more information, please visit the company website at www.duvalfdalaw.com.
ON BEHALF OF THE BOARD:
(signed) “Peter Bakema” CEO, President & Director
For further information contact:
Brisco Capital Partners Corp. Scott Koyich, President Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions, which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.